Law Office of Hong-min Jun · Chicago · Indianapolis
Pharmaceutical Developer
Biopharmaceuticals & mRNA Technology · China
Dr. C.W. holds a Ph.D. in Biochemistry from Peking University and has 9 years of experience in mRNA drug delivery systems. She played a pivotal role in developing lipid nanoparticle (LNP) formulations that were used in next-generation mRNA therapeutics for rare genetic diseases. Following the COVID-19 pandemic, her expertise in LNP technology became a strategic national asset in the U.S. biomanufacturing supply chain.
Post-COVID, mRNA technology is extremely competitive in the patent landscape. We needed to demonstrate that Dr. C.W.'s specific contributions — not just the field broadly — had national importance. The case required precise differentiation from hundreds of other LNP researchers.
Dr. C.W. developed a novel ionizable lipid compound that achieved 3x higher endosomal escape efficiency than existing formulations, a bottleneck that had limited mRNA therapeutics to vaccines. Her innovation opened the pathway to systemic mRNA delivery for rare diseases including Duchenne Muscular Dystrophy.
The Biden Administration's National Biotechnology and Biomanufacturing Initiative (NBBI) identified mRNA platform technology as a critical infrastructure priority. Dr. C.W.'s patents are cited in DoD BARDA contracts for pandemic preparedness, linking her work directly to national security.
Her proprietary LNP technology is subject to active BARDA contracts and DoD pandemic preparedness programs. PERM certification delays would interrupt time-sensitive federally-contracted R&D with national security implications, creating a compelling waiver justification.
mRNA technology cases post-2020 have a natural advantage in establishing national importance, but the key is specificity. Generic "mRNA is important" arguments fail — what succeeded here was connecting Dr. C.W.'s unique molecular innovation to specific BARDA contracts and DoD programs. Federal agency program officer letters carry extraordinary weight and are often underutilized in biopharmaceutical cases.
USCIS Approval Notice
Client identity redacted for confidentiality
Attorney Hong-min Jun can evaluate whether your background qualifies for NIW under the Dhanasar framework.
Request Free ConsultationAnalysis of AAO decision approving NIW for renewable energy researcher — publication impact and national interest contribution.
Why many NIW petitions fail at the National Importance prong in 2025, based on AAO decisions and practical case experience.
How the AAO evaluates recommendation letters in NIW petitions and what makes expert letters truly effective.
Every successful NIW case starts with a strategic assessment. Attorney Hong-min Jun will analyze your background against the Dhanasar framework and identify the strongest evidence for your petition.
Schedule Your Consultation